Editas Medicine (EDIT) Interest & Investment Income (2015 - 2025)
Editas Medicine (EDIT) reported Interest & Investment Income of $1.8 million for Q3 2025, down 48.13% year-over-year from $3.5 million in Q3 2024, and down 12.27% on a QoQ basis from $2.1 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Interest & Investment Income data on file, last reported at $1.8 million in Q3 2025.
- Quarterly Interest & Investment Income fell 48.13% year-over-year to $1.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.8 million (down 56.38% YoY) and the FY2024 annual result came in at $14.1 million, down 19.95% from the prior year.
- Interest & Investment Income slipped to $1.8 million in Q3 2025 per EDIT's latest filing, from $2.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5.1 million in Q3 2023 and bottomed at $134000.0 in Q1 2021.
- The 5-year median for Interest & Investment Income is $2.1 million (2025), against an average of $2.3 million.
- The widest annual swing landed in 2021, when Interest & Investment Income tumbled 91.4%; it then surged 1449.71% in 2022.
- Tracing EDIT's Interest & Investment Income over 5 years: stood at $175000.0 in 2021, then surged by 1449.71% to $2.7 million in 2022, then surged by 88.13% to $5.1 million in 2023, then tumbled by 76.46% to $1.2 million in 2024, then soared by 52.46% to $1.8 million in 2025.
- Per Business Quant, the three latest EDIT Interest & Investment Income figures stand at $1.8 million (Q3 2025), $2.1 million (Q2 2025), and $2.7 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 5.04 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.81 Mn |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 546,000.00 |
| Mar 31, 2022 | 469,000.00 |
| Dec 31, 2021 | 175,000.00 |
| Sep 30, 2021 | 152,000.00 |
| Jun 30, 2021 | 146,000.00 |
| Mar 31, 2021 | 134,000.00 |
| Dec 31, 2020 | 228,000.00 |
| Sep 30, 2020 | 226,000.00 |
| Jun 30, 2020 | 592,000.00 |
| Mar 31, 2020 | 1.56 Mn |
| Dec 31, 2019 | 1.65 Mn |
| Sep 30, 2019 | 1.68 Mn |
| Jun 30, 2019 | 1.93 Mn |
| Mar 31, 2019 | 2.06 Mn |
| Dec 31, 2018 | 1.20 Mn |
| Sep 30, 2018 | 1.02 Mn |
| Jun 30, 2018 | 780,000.00 |
| Mar 31, 2018 | 438,000.00 |
| Sep 30, 2017 | -46,000.00 |
| Jun 30, 2017 | -446,000.00 |
| Mar 31, 2017 | -610,000.00 |
| Dec 31, 2016 | -357,000.00 |
| Sep 30, 2016 | 142,000.00 |
| Jun 30, 2016 | 153,000.00 |
| Mar 31, 2016 | 124,000.00 |
| Dec 31, 2015 | -34,000.00 |
| Sep 30, 2015 | -44,000.00 |
| Jun 30, 2015 | -34,000.00 |
| Mar 31, 2015 | -31,000.00 |